- Home
- KMDA vs EBS Comparison
KMDA vs EBS Comparison
Compare KMDA & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- EBS
- Stock Information
- Founded
- KMDA 1990
- EBS 1998
- Country
- KMDA Israel
- EBS United States
- Employees
- KMDA N/A
- EBS N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- KMDA Health Care
- EBS Health Care
- Exchange
- KMDA Nasdaq
- EBS Nasdaq
- Market Cap
- KMDA 426.0M
- EBS 393.9M
- IPO Year
- KMDA N/A
- EBS 2006
- Fundamental
- Price
- KMDA $6.71
- EBS $4.77
- Analyst Decision
- KMDA Strong Buy
- EBS Strong Buy
- Analyst Count
- KMDA 3
- EBS 3
- Target Price
- KMDA $14.67
- EBS $14.33
- AVG Volume (30 Days)
- KMDA 139.3K
- EBS 1.2M
- Earning Date
- KMDA 03-05-2025
- EBS 04-30-2025
- Dividend Yield
- KMDA 2.99%
- EBS N/A
- EPS Growth
- KMDA 66.67
- EBS N/A
- EPS
- KMDA 0.25
- EBS N/A
- Revenue
- KMDA $160,953,000.00
- EBS $1,043,600,000.00
- Revenue This Year
- KMDA $11.45
- EBS N/A
- Revenue Next Year
- KMDA $9.94
- EBS $19.88
- P/E Ratio
- KMDA $26.77
- EBS N/A
- Revenue Growth
- KMDA 12.93
- EBS N/A
- 52 Week Low
- KMDA $4.74
- EBS $1.82
- 52 Week High
- KMDA $9.15
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- KMDA 44.68
- EBS 28.20
- Support Level
- KMDA $6.44
- EBS $4.53
- Resistance Level
- KMDA $7.17
- EBS $5.46
- Average True Range (ATR)
- KMDA 0.20
- EBS 0.38
- MACD
- KMDA -0.02
- EBS 0.03
- Stochastic Oscillator
- KMDA 37.36
- EBS 16.47
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.